ビミラリシブ
ビミラリシブ 物理性質
- 沸点 :
- 643.7±65.0 °C(Predicted)
- 比重(密度) :
- 1.418±0.06 g/cm3(Predicted)
- 貯蔵温度 :
- Store at -20°C
- 溶解性:
- DMSO:22.0(Max Conc. mg/mL);53.48(Max Conc. mM)
DMF:10.0(Max Conc. mg/mL);24.31(Max Conc. mM)
Ethanol:2.0(Max Conc. mg/mL);4.86(Max Conc. mM)
- 外見 :
- A crystalline solid
- 酸解離定数(Pka):
- 4.92±0.10(Predicted)
安全性情報
- リスクと安全性に関する声明
- 危険有害性情報のコード(GHS)
ビミラリシブ 価格
| メーカー |
製品番号 |
製品説明 |
CAS番号 |
包装 |
価格 |
更新時間 |
購入 |
ビミラリシブ 化学特性,用途語,生産方法
効能
抗悪性腫瘍薬, PI3キナーゼ阻害薬
説明
Bimiralisib is a potent and orally bioavailable inhibitor of phosphatidylinositol 3-kinases (PI3Ks; IC
50s = 33, 661, 708, and 451 nM for PI3Kα, PI3Kβ, PI3Kγ, and PI3Kδ, respectively) and the mammalian target of rapamycin (mTOR; IC
50 = 89 nM). It is selective for these kinases over a panel of cell surface and nuclear receptors, membrane channels, transporters, kinases, proteases, and phosphodiesterases at a concentration of 10 μM. Bimiralisib has anticancer activity with an average GI
50 value of 0.7 μM across the National Cancer Institute (NCI) 60 human cancer cell line panel.
In vivo, bimiralisib (5-15 mg/kg) reduces tumor growth in a dose-dependent manner in a PC3 prostate cancer mouse xenograft model. Formulations containing bimiralisib are under clinical investigation for the treatment of relapsed and refractory lymphoma and advanced solid tumors.
ビミラリシブ 上流と下流の製品情報
原材料
準備製品
ビミラリシブ 生産企業
Global( 75)Suppliers
1225037-39-7(ビミラリシブ)キーワード:
- 1225037-39-7
- 5-(4,6-dimorpholino-1,3,5-triazin-2-yl)-4-(trifluoromethyl)pyridin-2-amine
- PI3K-IN-2
- PQR309
- Bimiralisib
- PQR309 Bimiralisib
- CS-2024
- PQR309;PQR 309;PQR-309
- Bimiralisib (PQR309)(free base)
- PQR-309, >98%
- 2-Pyridinamine,5-(4,6-di-4-morpholinyl-1,3,5-triazin-2-yl)-4-(trifluoromethyl)-
- BIMIRALISIB;PQR309;PQR 309;PQR-309
- Bimiralisib (PQR309)
- 5-(4,6-Di-4-morpholinyl-1,3,5-triazin-2-yl)-4-(trifluoromethyl)-2-pyridinamine
- ビミラリシブ